The DCGI has given ENTOD Pharma approval for phase 3 trials of its myopia eye drop

Myopia is the most common cause of visual impairment in children, and according to an AIIMS research, 17% of children, or 1 in every 6 children in India between the ages of 5 and 15 years, suffer from myopia."

ENTOD Pharmaceuticals stated on Tuesday that it has gained authorisation from the Drug Controller General of India (DCGI) to conduct phase 3 studies for its 0.05 percent atropine eye drops, which are used to treat eye issues.

MYATRO 0.01 percent eye drops, manufactured by a Maharashtra-based pharmaceutical business, are used to treat eye issues such as myopia, which occurs when a kid can easily see adjacent items but has difficulty seeing distant ones.

According to the company, this increased strength of low-dose atropine eye drops is not commercially available anywhere in the world, and ENTOD Pharmaceuticals would be the first to launch it in India to a successful demonstration of safety and efficacy in clinical studies.

Low-dose atropine has emerged as an effective method for slowing the growth of myopia in children, attracting the interest of ophthalmologists. A recent LAMP (Low-Concentration Atropine for Myopia Progression) research published by the American Academy of Ophthalmology (AAO) found that atropine eye drops containing 0.05, 0.025, and 0.01 percent atropine decreased myopia progression and were well tolerated by children. However, the company stated that of the three concentrations, 0.05 percent atropine was the most efficient in limiting AL elongation and SE advancement over a year.

"We have already recruited several clinical research sites across India to begin phase 3 trial studies, and we hope to be the first company in the world to receive approval from the Drug Controller General of India (DCGI) to market 0.05 per cent atropine eye drops," stated “ Nikkhil K Masurkar, Executive Director of ENTOD Pharmaceuticals.

"This new therapeutic addition to the low-dose atropine spectrum would help us to combat the epidemic of childhood myopia in India," he added. Myopia is the most common cause of visual impairment in children, and according to an AIIMS research, 17% of children, or 1 in every 6 children in India between the ages of 5 and 15 years, suffer from myopia."

Doctors state that myopia is a growing concern that causes an abnormal curvature of the cornea or elongation of the eyeball such that light no longer focuses directly on the retina.

"Excessive laptop and smartphone screen exposure times, particularly due to online homeschooling during the pandemic," said Dr. Namrata Sharma, General Secretary of the All India Ophthalmological Society, "has significantly increased the incidence of myopia in younger children, which could lead to visual complications in later life such as glaucoma, early cataract development, retinal detachment, and myopic maculopathy" (AIOS).

Low-Dose Atropine eye drops are one of the most feasible therapy options available to swiftly decrease the onset of myopia and enhance a child's vision.

"Atropine therapy is now part of standard clinical practice in India and shows significant potential as a treatment for managing myopia," she noted. The clinical studies will allow us to learn more about how atropine 0.05 percent may be used efficiently and safely as a solution to rising myopia issues not only in India but throughout the world.

Tags : #Myopia #childrenhealthcare #ENTOD #DCGI #innovations #healthcare #medicircle #smitakumar #visualimpairment

Related Stories

12 Sep

Newly Published ROSacea COnsensus (ROSCO) Expert Recommendations Encourage Dermatologists to Upweight Burden-related Discussions, Aim For 'Complete Clearance' of Symptoms and Consider Combination Therapy For Severe Patients

The rosacea treatment algorithm, developed by ROSCO in 2017, has been updated with several new recommendations including the use of combination therapy to benefit severe patients and those presenting with multiple features, in line with latest clinical evidence.

View

-Advertisements-




Trending Now

Will India’s Healthcare Budget Support a Future of Robotic Surgeries?February 22, 2025
Is the World on the Brink of Another Pandemic? Scientists Discover a New Bat VirusFebruary 22, 2025
Newcastle University Expands Academic and Research Collaborations in IndiaFebruary 21, 2025
Get Ready to #BibaUp! Kriti Sanon Unveils the Season’s Most Stylish Summer CollectionFebruary 21, 2025
A Rare Condition: Surgery Saves 2-Day-Old Baby as Organs Shift Into ChestFebruary 21, 2025
Odisha’s Bold Healthcare Vision: A Rs 12,000 Crore Blueprint for Universal Health AccessFebruary 21, 2025
Young India’s Health Crisis: Why Insurance Claims Are Rising Among 25-35 Year OldsFebruary 21, 2025
India vs. Trump’s Pharma Tariff: The Battle Over Affordable MedicineFebruary 21, 2025
Foreign Medical Aspirants in Trouble: NMC’s Warning on Pending Eligibility CertificatesFebruary 21, 2025
Think Your Work Music Helps You Focus? Science Says Think AgainFebruary 21, 2025
Is Your Home’s Air Poisoning You? Shocking New Study Reveals Hidden Indoor Pollution RisksFebruary 20, 2025
The Society of Automotive Engineers & B V Raju Institution of Technology; to host the globally prestigious E-BAJA 2025; at Hyderabad!February 20, 2025
Eat right for your heart to beat rightFebruary 19, 2025
Aakash Healthcare and Medtronic Inaugurate North India’s First Dedicated Vein ClinicFebruary 19, 2025
Urgent and accelerated HIV service delivery with equity and rights is critical to end AIDSFebruary 19, 2025
Fasting Fad or Future Health Threat? Why Teens Should Think Twice Before Intermittent Fasting February 19, 2025
Public Hospitals Go High-Tech: AIIMS Delhi Leads India’s Robotic Surgery WaveFebruary 19, 2025
Screen Time and Healthy Habits: Navigating Optimal Development in ChildrenFebruary 18, 2025
SRM Global Hospitals Launches WOW, a Centre Exclusively for Women’s Health and WellnessFebruary 18, 2025
The Hidden Dangers of Scented Candles: Aesthetic Bliss or Silent Health Hazard?February 18, 2025